Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,461 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Solid Neoplasm Clear all
Completed Phase 3 Interventional Results available

Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy

NCT00956813
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Menopausal Symptoms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
flaxseed, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
107
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 71 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 23, 2026, 6:51 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
Interventions
ABBV-400, Trifluridine/Tipiracil, Bevacizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 23, 2026, 6:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

NCT02608268
View directory record Official record
Conditions
Advanced Malignancies
Interventions
MBG453, PDR001, Decitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 23, 2026, 6:51 AM EDT
Terminated Phase 2 Interventional Results available

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

NCT04383210
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions
Seribantumab
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

NCT01276496
View directory record Official record
Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Cilengitide, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

NCT04084951
View directory record Official record
Conditions
Adult Solid Tumor
Interventions
SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Biological · Drug
Lead sponsor
SQZ Biotechnologies
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 23, 2026, 6:51 AM EDT
Recruiting Phase 1 Interventional

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

NCT07361562
View directory record Official record
Conditions
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
Interventions
CGT4255
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

NCT03790488
View directory record Official record
Conditions
Cancer
Interventions
JTX-4014
Drug
Lead sponsor
Jounce Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 23, 2026, 6:51 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

NCT03739827
View directory record Official record
Conditions
Malignant Solid Tumors, Other Neoplasms Solid Tumors, Pediatric Solid Tumor, Refractory Solid Tumors, Solid Tumor
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Weeks and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2032
U.S. locations
3
States / cities
Bethesda, Maryland • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

NCT02639546
View directory record Official record
Conditions
Solid Tumors
Interventions
Cobimetinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Months to 30 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Little Rock, Arkansas • Orlando, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer

NCT00002939
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants

NCT00098969
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
resveratrol
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 23, 2026, 6:51 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

NCT06326411
View directory record Official record
Conditions
Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult, MAPK Pathway Gene Mutation
Interventions
NST-628
Drug
Lead sponsor
Nested Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
San Francisco, California • Westwood, Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

SMP-3124LP in Adults With Advanced Solid Tumors

NCT06526819
View directory record Official record
Conditions
Solid Tumor
Interventions
SMP3124LP
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer

NCT00005807
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BMS-247550
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

NCT00004057
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
L-778,123, paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 23, 2026, 6:51 AM EDT
Terminated Phase 1 Interventional Results available

Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

NCT03249792
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
MK-2118 (IT), MK-2118 (SC), Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

NCT01723020
View directory record Official record
Conditions
Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Glioblastoma, Multiple Myeloma
Interventions
AMG 232
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Santa Monica, California • Norwalk, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 23, 2026, 6:51 AM EDT
Terminated Phase 1 Interventional

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02936102
View directory record Official record
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
Interventions
FAZ053, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 23, 2026, 6:51 AM EDT
Recruiting Phase 1 Interventional

A Study of PHST001 in Advanced Solid Tumors

NCT06840886
View directory record Official record
Conditions
Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
Interventions
PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI, FOLFOX, Gemcitabine, Mirvetuximab Soravtansine, Trastuzumab Deruxtecan
Biological · Drug
Lead sponsor
Pheast Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 23, 2026, 6:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer

NCT01445522
View directory record Official record
Conditions
Neoplasms, Lymphoma
Interventions
ABT-888, Cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Duarte, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 23, 2026, 6:51 AM EDT